Mechanisms by which Polarity Proteins Regulate Initiation and Progression of Brea
极性蛋白调节 Brea 起始和进展的机制
基本信息
- 批准号:7668146
- 负责人:
- 金额:$ 24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-03-01 至 2009-01-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAffectAntineoplastic AgentsApoptosisArchitectureBiological MarkersBreastCarcinomaCell DeathCell PolarityCell ProliferationCell ShapeCellsClassComplexDepthDevelopmentDiseaseDisruptionDrug Delivery SystemsDrug resistanceEpithelialEpithelial CellsEquilibriumFundingGenesGoalsIceMLLT4 geneMaintenanceMalignant - descriptorMalignant NeoplasmsMesenchymalMolecularMutationNormal CellNormal tissue morphologyNumbersOncogenesOncogenicPathologistPathway interactionsPlayPremalignantProteinsReceptor Protein-Tyrosine KinasesRoleRole playing therapySignal TransductionStimulation of Cell ProliferationStructureThinkingTissuescell behaviorcell motilityepithelial to mesenchymal transitiongene interactionin vivomalignant breast neoplasmnoveltumortumor progressiontumorigenesis
项目摘要
Almost all malignant breast cancers originate from epithelial cells within glandular structures. Normal
epithelial architecture/polarity is critical to maintain the delicate balance between a cell and its
microenvironment; disruption of this balance can result in the aberrant cell behavior observed during
initiation and progression of carcinoma. In fact, pathologists routinely use changes in cell and tissue
architecture to understand cancer progression and make assessments for treatment options. Despite the
appreciation of the importance of cell architecture, the mechanism by which cell and tissue architecture is
disrupted in carcinoma remains poorly understood. It is likely that understanding the molecular mechanisms
by which cell and tissue and architecture is deregulated in carcinoma will not only allow us to have a better
understanding of changes in tumor microenvironment but also identify a new class of biomarkers and drug
targets.
During the past funding period we discovered that oncogenes interact with polarity regulators to
disrupt cell polarity and three-dimensional organization of epithelial structures. The interaction was
independent of the ability of oncogenes to induce cell proliferation. Surprisingly, the oncogene-polarity
genes interaction was required for protecting cells from apoptosis. Thus, polarity genes play important roles
in carcinoma. They are required for oncogenes to induce changes in cell and tissue architecture and for
protecting cells from death. I think we have just begun to scrape the ice, much remains to be understood on
the molecular mechanisms by which polarity pathways cooperate with oncogenes during initiation and
progression of carcinoma.
In this proposal we build on our results from the previous funding period to address the following: 1)
Develop a deeper understanding of the mechanism by which ErbB2 interacts with polarity pathways; (2)
Determine how polarity pathways protects cells from apoptosis and what roles does this play during
development of drug resistance (3) Determine how polarity pathways cooperate with ErbB2 to promote
epithelial to mesenchymal transition and malignant progression.
Thus the goal of this proposal is to take a new perspective - understand carcinoma initiation and
progression as a function of deregulated cell polarity pathways.
几乎所有恶性乳腺癌源自腺体结构内的上皮细胞。普通的
上皮结构/极性对于维持细胞及其之间的微妙平衡至关重要
微环境;这种平衡的破坏会导致在
癌的启动和进展。实际上,病理学家通常在细胞和组织中使用变化
了解癌症进展并评估治疗方案的建筑。尽管有
欣赏细胞结构的重要性,细胞和组织结构的机制
癌症中断仍然知之甚少。理解分子机制很可能
细胞,组织和建筑在癌中的管制不仅可以使我们变得更好
了解肿瘤微环境的变化,但也确定了一类新的生物标志物和药物
目标。
在过去的资金期间,我们发现Oncogenes与极性调节器相互作用
破坏细胞极性和上皮结构的三维组织。相互作用是
独立于癌基因诱导细胞增殖的能力。令人惊讶的是,致癌基因
保护细胞免受细胞凋亡的影响需要基因相互作用。因此,极性基因起着重要作用
在癌中。它们是癌基因诱导细胞和组织结构的变化所必需的
保护细胞免受死亡。我认为我们刚刚开始刮擦冰,还有很多待了解
极性途径在开始期间与癌基因合作的分子机制和
癌的进展。
在此提案中,我们基于以下资金期的结果,以解决以下内容:1)
对ERBB2与极性途径相互作用的机制有了更深入的了解。 (2)
确定极性途径如何保护细胞免受凋亡的侵蚀以及在此期间起什么作用
耐药性的发展(3)决定了极性途径如何与ERBB2合作以促进
上皮到间充质转变和恶性进展。
因此,该提案的目的是采用新的观点 - 了解癌的启动和
进展是失控的细胞极性途径的函数。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SENTHIL K MUTHUSWAMY其他文献
SENTHIL K MUTHUSWAMY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SENTHIL K MUTHUSWAMY', 18)}}的其他基金
2023 Mammary Gland Biology Gordon Research Conference and Gordon Research Seminar
2023年乳腺生物学戈登研究会议暨戈登研究研讨会
- 批准号:
10682769 - 财政年份:2023
- 资助金额:
$ 24万 - 项目类别:
Cell polarity pathways and ErbB2 mediated tumorigenesis
细胞极性途径和 ErbB2 介导的肿瘤发生
- 批准号:
8409834 - 财政年份:2003
- 资助金额:
$ 24万 - 项目类别:
Early events of carcinoma induced by ErbB receptors
ErbB 受体诱导的癌症早期事件
- 批准号:
7487609 - 财政年份:2003
- 资助金额:
$ 24万 - 项目类别:
Early events of carcinoma induced by ErbB receptors
ErbB 受体诱导的癌症早期事件
- 批准号:
6560710 - 财政年份:2003
- 资助金额:
$ 24万 - 项目类别:
Cell polarity pathways and ErbB2 mediated tumorigenesis
细胞极性途径和 ErbB2 介导的肿瘤发生
- 批准号:
8205028 - 财政年份:2003
- 资助金额:
$ 24万 - 项目类别:
Cell polarity pathways and ErbB2 mediated tumorigenesis
细胞极性途径和 ErbB2 介导的肿瘤发生
- 批准号:
7584332 - 财政年份:2003
- 资助金额:
$ 24万 - 项目类别:
Cell polarity pathways and ErbB2 mediated tumorigenesis
细胞极性途径和 ErbB2 介导的肿瘤发生
- 批准号:
7998161 - 财政年份:2003
- 资助金额:
$ 24万 - 项目类别:
Early events of carcinoma induced by ErbB receptors
ErbB 受体诱导的癌症早期事件
- 批准号:
7009932 - 财政年份:2003
- 资助金额:
$ 24万 - 项目类别:
Cell polarity pathways and ErbB2 mediated tumorigenesis
细胞极性途径和 ErbB2 介导的肿瘤发生
- 批准号:
7753677 - 财政年份:2003
- 资助金额:
$ 24万 - 项目类别:
Early events of carcinoma induced by ErbB receptors
ErbB 受体诱导的癌症早期事件
- 批准号:
6856492 - 财政年份:2003
- 资助金额:
$ 24万 - 项目类别:
相似国自然基金
海洋缺氧对持久性有机污染物入海后降解行为的影响
- 批准号:42377396
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
氮磷的可获得性对拟柱孢藻水华毒性的影响和调控机制
- 批准号:32371616
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
还原条件下铜基催化剂表面供-受电子作用表征及其对CO2电催化反应的影响
- 批准号:22379027
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
CCT2分泌与内吞的机制及其对毒性蛋白聚集体传递的影响
- 批准号:32300624
- 批准年份:2023
- 资助金额:10 万元
- 项目类别:青年科学基金项目
在轨扰动影响下空间燃料电池系统的流动沸腾传质机理与抗扰控制研究
- 批准号:52377215
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
Parallel Characterization of Genetic Variants in Chemotherapy-Induced Cardiotoxicity Using iPSCs
使用 iPSC 并行表征化疗引起的心脏毒性中的遗传变异
- 批准号:
10663613 - 财政年份:2023
- 资助金额:
$ 24万 - 项目类别:
Cancer Therapeutics and Host Response Research Program
癌症治疗和宿主反应研究计划
- 批准号:
10625756 - 财政年份:2023
- 资助金额:
$ 24万 - 项目类别:
Investigating mitochondrial dysfunction in high-risk prostate cancer
研究高危前列腺癌中的线粒体功能障碍
- 批准号:
10570345 - 财政年份:2023
- 资助金额:
$ 24万 - 项目类别:
Small molecule modulation of 14-3-3 protein-protein interactions
14-3-3 蛋白质-蛋白质相互作用的小分子调节
- 批准号:
10607941 - 财政年份:2023
- 资助金额:
$ 24万 - 项目类别:
Defining kinase interaction pathways to enhance anti-cancer efficacy and minimize associated morbidities of kinase inhibitor drugs.
定义激酶相互作用途径,以增强抗癌功效并最大限度地减少激酶抑制剂药物的相关发病率。
- 批准号:
10644554 - 财政年份:2023
- 资助金额:
$ 24万 - 项目类别: